Anna Luisa Di Stefano: GBM with EGFR Alterations Treated with Osimertinib
Anna Luisa Di Stefano, Neuro-oncologist at AUSL Toscana Nord Ovest, Spedali Riuniti di Livorno, Neurosurgery Department, shared on LinkedIn about a recent paper by Federico Villanacci et al. published in Society for Translational Oncology:
“Just published!
In this article we present the cases of two GBM patients with EGFR alterations treated with osimertinib. One patient had an EGFR amplification and the other one an EGFR mutation associated with potential osimertinib sensitivity. Both patients progressed rapidly under osimertinib.
As more and more GBM patients undergo NGS, it is not unfrequent to identify EGFR mutations predictive of osimertinib sensitivity. In our experirnce osimertinib failed to demonstrate efficacy in the few GBM patients with possible osimertinib sensitive EGFR mutations.
Negative results matter!”
Title: Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib
Authors: Federico Villanacci , Diego Prost , Francesco Pieri , Julien Boetto , Vanna Zucchi , Andrea Giusti , Julian Jacob , Lucia Nichelli , Samanta Cupini , Giacomo Allegrini , Mauro Della Porta , Orazio Santo Santonocito , Mehdi Touat , Anna Luisa Di Stefano
More about GBM.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023